Using telemonitoring to manage side effects in cancer patients receiving immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a telemonitoring system designed to manage side effects in patients with melanoma, lung cancer, or renal cancer who are being treated with the immunotherapy combination of nivolumab and ipilimumab or adjuvant nivolumab monotherapy. Patients will complete a simplified medical questionnaire weekly, which will provide clinicians with regular feedback on their symptoms. The goal is to reduce the time between the onset of adverse events and their reporting to healthcare providers, thereby improving patient management. This randomized prospective trial aims to assess the efficacy of this remote monitoring approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Patients diagnosed with melanoma, or lung cancer or renal cancer
* Patients starting a treatment with a combination of immunotherapy of nivolumab + ipilimumab (NB: patients who have already received immunotherapy in the past may be included)
* Patients comfortable with the use of digital tools and computing
* Patients who agree to participate to the telemonitoring and signed consent form

Exclusion Criteria:

* Pregnant, parturient and lactating women
* Patients under legal protection measure or deprived of their liberty
* Patients not affiliated to a social security scheme (schemes such as the AME) or beneficiaries of a similar regime (foreign person, outside the EU)

Where it's running

• Centre Hospitalier Lyon Sud - Department of Medical Oncology
  Pierre-Bénite, France Recruiting
• Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer Institute
  Pierre-Bénite, France Recruiting
• Hôpital Lyon Sud - Department of pneumology,Thoracic oncology
  Pierre-Bénite, France Recruiting
• Groupement hospitalier Est - Multidisciplinary oncological platform
  Bron, France Not yet recruiting
• Hôpital Louis Pradel - Department of Pneumology
  Bron, France Not yet recruiting
• University hospital of Grenoble Alpes - Department of dermatology
  Grenoble, France Not yet recruiting

Study contacts

• Principal investigator: Stéphane DALLE — Department of Dermatology, HCL-Cancer Institute
• Study coordinator: Stéphane DALLE
• Email: stephane.dalle@chu-lyon.fr
• Phone: 0478861679

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Relatlimab, nivolumab, and ipilimumab for melanoma that has spread to the brain

  This trial will test whether the combination of relatlimab, nivolumab, and ipilimumab can help adults with melanoma brain metastases, including those with and without symptoms.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06712927

• Triplet combination of Relatlimab, Nivolumab, and Ipilimumab in first-line metastatic melanoma

  A first-line trial tests whether a three-drug combo can help people with metastatic melanoma, starting at a recommended dose.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06683755

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Local injection of ipilimumab and nivolumab for high-risk stage II melanoma

  This study is testing if injecting a combination of two immune-boosting drugs directly into the skin can help people with high-risk stage II melanoma by reducing the chance of cancer spreading.

  Recruiting at 2 sites Phase 1/2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06240143

• Combining Sarilumab with Other Treatments for Advanced Melanoma

  This study is testing a new combination of treatments for people with advanced melanoma to see if it helps them feel better and live longer.

  Recruiting at 4 sites Phase 2 NYU Langone Health · Los Angeles, California and 3 other locations · NCT05428007

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.